Abstract
Coca-Cola will report its first-quarter results on April 28, 2026 Pre-Market, with current expectations centering on mid–single to low–double digit organic growth translating into revenue of about 12.26 billion US dollars and adjusted EPS near $0.81.
Market Forecast
Based on the latest quarter’s disclosures and near‑term models, the market’s baseline for this quarter is revenue of 12.26 billion US dollars, up 10.05% year over year, and adjusted EPS of $0.81, up 13.60% year over year; consensus also implies EBIT of 4.21 billion US dollars, up 15.45% year over year. No explicit quarterly margin forecast is embedded in the models; the last reported gross profit margin was 60.05% and net profit margin was 19.21%, serving as a reasonable baseline pending the print.
Coca-Cola’s core engine continues to be its concentrates business, which delivered 28.46 billion US dollars in revenue in the last reported period, supported by positive pricing and a 1% year‑over‑year increase in concentrate sales volume during 2025; management’s 2026 outlook for 4%–5% organic revenue growth pairs with disciplined reinvestment. The most promising near‑term commercial opportunity sits in the finished‑products portfolio at 19.48 billion US dollars of revenue, where brand activations and innovation (including partnerships and package mixes) are expected to lift volumes, with full‑year organic revenue growth guided to 4%–5% year over year as a directional marker for this segment’s trajectory.
Last Quarter Review
Coca-Cola’s prior quarter (reported on February 10, 2026) delivered revenue of 11.82 billion US dollars, up 3.62% year over year, with a 60.05% gross margin, GAAP net income attributable to shareholders of 2.27 billion US dollars, a 19.21% net profit margin, and adjusted EPS of $0.58, up 5.46% year over year.
A notable item was a 32% decline in operating income for the quarter, primarily due to a 0.96 billion US dollar non‑cash impairment on the BODYARMOR trademark and currency headwinds; excluding these effects, comparable currency‑neutral operating income increased 13%. By business, concentrates remained the anchor with 28.46 billion US dollars in revenue across the last reported period and concentrate sales volume up 1% year over year in 2025, while company‑wide fourth‑quarter organic growth reflected a 4% uptick in concentrate shipments and 1% in price/mix.
Current Quarter Outlook
Concentrates: Pricing discipline and shipment cadence point to solid operating leverage
The concentrates franchise should remain the primary driver of profitability this quarter, benefiting from the structural economics of the model and the shipment cadence implied by management’s full‑year framework. With consensus revenue up 10.05% year over year and EBIT up 15.45% year over year, the gap between top‑line and operating income growth suggests incremental margin expansion tied to favorable mix and cost control, even if gross margin is held near the last reported 60.05% as a planning assumption. Concentrate sales volume grew 1% in 2025, and the company indicated organic revenue growth of 4%–5% for 2026; layering normal seasonality onto that posture supports expectations that Q1 concentrate shipments will track modestly ahead of volume, with pricing/mix bridging to double‑digit total revenue growth.
Geographic dispersion still matters for quarterly variance, as the shipment pattern for concentrates can diverge from unit‑case consumption across regions in any single quarter. That said, the portfolio’s breadth across sparkling, flavors, and low/no‑sugar variants typically stabilizes mix and supports gross margin resilience. With sweetener and packaging inputs trending mixed into early 2026, the concentrates model’s lower direct commodity exposure versus finished goods helps insulate aggregate margins. Assuming FX remains a modest tailwind for the year (as guided), the translation effect should be manageable for Q1, and any small uplift would fall through to reported sales and EBIT.
The near‑term watch items are shipment phasing and on‑premise demand normalization. If channel inventories are balanced as expected, concentrates should deliver on timing while sustaining price/mix at mid‑single digits, thereby preserving the spread between revenue and EBIT growth rate implied by consensus. Execution risk looks bounded in the quarter given the company’s emphasis on disciplined price architecture and targeted marketing.
Finished products and brand activations: Marketing flywheels to underpin volume and mix
In the finished‑products portfolio, Coca-Cola is leaning on synchronized brand activity to maintain volume momentum and mix quality. The recently announced multiyear global marketing partnership that brings Sprite back as the official global soft drink of the NBA increases brand visibility and engagement across key events and digital touchpoints. While the bulk of the revenue impact will build over several quarters, the activation window around the late‑season and playoff calendars should still provide promotional energy to the sparkling portfolio in Q1 and Q2, enhancing consumer pull and retail feature support.
Innovation and package architecture remain central to sustaining price realization without compromising affordability. Smaller, premium‑per‑ounce packages and multipacks tailored to at‑home occasions continue to support a healthy price/mix profile, while disciplined promotional cadence aims to protect brand equity. With management guiding 4%–5% organic revenue growth for 2026, finished‑product performance in Q1 is likely to track in line with that algorithm, with volume gradually improving where investments in availability and in‑store execution are concentrated.
On the cost side, direct commodity exposures (sweeteners, resin for PET, and aluminum in certain geographies) remain a monitoring item. However, procurement programs and hedging should limit quarter‑to‑quarter variability. The net of these factors suggests finished products will contribute to the consolidated revenue step‑up this quarter, with gross margin effects moderated by mix management and productivity, thereby complementing the higher‑margin concentrates stream.
Key stock drivers this quarter: Margins, FX translation, and one‑time compares
Margin progression is a primary focus for investors into the print. Consensus assumes double‑digit EBIT growth against revenue up about 10%, implying some operating leverage despite normal seasonal reinvestment. Delivery against that spread will hinge on price/mix durability, procurement savings, and overhead discipline. The last reported gross margin of 60.05% offers a strong base; even small improvements in concentrate mix and lower promotional intensity in certain markets could incrementally lift margins, while any lingering inflation in inputs would slow but likely not derail that trajectory.
Foreign exchange is a secondary swing factor. The company’s full‑year 2026 outlook contemplated a roughly 1% tailwind to organic revenue from currency, with divestitures expected to be a headwind later in the year. For Q1 specifically, spot rates suggest translation effects should be contained; an absence of adverse currency moves would keep the focus on underlying organic trends. If currencies are steadier than anticipated, upside to reported sales and EBIT could emerge versus local‑currency growth.
One‑time effects create easier compares in certain P&L lines. The fourth‑quarter impairment on BODYARMOR was non‑cash and does not repeat in Q1, simplifying the operating income bridge. At the same time, management emphasized continued investment behind priority brands and capabilities, so operating expense reinvestment may offset part of the gross margin tailwinds. Net‑net, the consolidated setup supports the consensus view of revenue and EPS growth outpacing unit volume, driven by mix, pricing discipline, and sustained commercial execution.
Analyst Opinions
Across the January 1, 2026 to April 21, 2026 window, the balance of published previews and rating actions skews decisively bullish, with at least four buy/overweight opinions versus no outright bearish calls in the period. Jefferies reiterated a Buy rating twice in the period, lifting its price target to $90 on March 16, 2026 and setting $88 on April 1, 2026, citing confidence in the company’s ability to compound organic revenue in the mid‑single digits while expanding margins through concentrate mix and marketing productivity. BNP Paribas maintained an Outperform rating with an $89 target on February 13, 2026, highlighting consistent price/mix, strong cash generation, and a line of sight to comparable EPS growth in the high‑single digits for 2026. Argus raised its target to $89 from $84 on February 23, 2026 while maintaining a Buy, pointing to resilient demand across the sparkling portfolio and capital allocation that supports both reinvestment and shareholder returns.
The majority view emphasizes three themes for this quarter: first, that revenue growth near 10% year over year is credible given the underlying organic revenue algorithm and shipment timing in concentrates; second, that operating leverage should materialize as marketing spend is prioritized toward higher‑ROI programs, enabling double‑digit EBIT growth even as investments continue; and third, that cash conversion remains robust, preserving flexibility for dividends and buybacks without compromising strategic initiatives. Analysts also note that the non‑cash impairment recognized in the fourth quarter is not indicative of current‑period demand trends, and therefore does not cloud the near‑term earnings quality.
In terms of what would validate the bullish stance on the print, institutions are watching for confirmation that price/mix is holding at mid‑single digits or better, that concentrate shipments are pacing in line with unit‑case momentum, and that gross margins remain anchored around 60% with signs of incremental improvement. Any evidence that the NBA‑linked brand activations are enhancing retail velocity and digital engagement would add confidence to second‑quarter and summer sell‑through. Finally, steady FX translation and a clean P&L (absent unusual items) would support the consensus EPS of about $0.81, with potential upside if opex timing is favorable.
Overall, the predominant institutional take heading into April 28, 2026 is constructive: the earnings cadence is expected to accelerate from the fourth quarter’s base, management’s 2026 guide frames achievable mid‑single digit organic growth, and the near‑term margin bridge looks intact. That combination underpins the cluster of Buy and Outperform ratings and the upwardly revised price targets cited during the period, setting the stage for a solid pre‑market update if revenue, EBIT, and EPS land at or above the figures embedded in current models.
Comments